

## The reaction of 1,5,6-trimethylbenzimidazole with 1,3-diphenylprop-2-yn-1-one and water: en route to $\beta$ -amino enones and benzodiazocinones

Kseniya V. Belyaeva, Ludmila V. Andriyankova, Lina P. Nikitina, Andrei V. Afonin, Igor A. Ushakov, Anastasiya G. Mal'kina and Boris A. Trofimov\*

A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 664033 Irkutsk, Russian Federation. Fax: +7 395 241 9346; e-mail: boris\_trofimov@irioch.irk.ru

DOI: 10.1016/j.mencom.2015.07.006

Refluxing the mixture of 1,5,6-trimethylbenzimidazole, 1,3-diphenylprop-2-yn-1-one and water in MeCN for 70 h affords (*Z*)-3-[2-(*N*-formyl-*N*-methylamino)-4,5-dimethylphenylamino]-1,3-diphenylprop-2-en-1-one (75%) and 1,8,9-trimethyl-3,5-diphenyl-1,6-benzodiazocin-2(1*H*)-one (13%).


Vinyl carbanions accompanied by inner ammonium cations, the zwitterionic adducts of imidazoles to electron-deficient acetylenes, invoke a growing interest as convenient intermediates for functionalization of the imidazole ring.<sup>1</sup> In the presence of water, 1-substituted imidazoles undergo the ring opening to stereoselectively produce functionalized (*Z,Z*)-diazadienes.<sup>2</sup> In the case of benzimidazoles, this reaction may lead to *N*-aryl-substituted  $\beta$ -amino enones.

In 1979, the reaction of 1-substituted benzimidazoles with 4-phenylbut-3-yn-2-one (boiling in toluene for 3–8 days) was studied.<sup>3</sup> However, instead of the expected  $\beta$ -amino enones, benzodiazocinones, the products of the benzimidazole ring expansion were isolated in 7–9% yields, whereas the formation of any open-ring compounds was not mentioned.<sup>3</sup> Later, the structure of these benzodiazocinones was confirmed by X-ray analysis.<sup>4</sup> Since then no information about this reaction appeared in the literature.

Meanwhile, *N*-aryl-substituted  $\beta$ -amino enones and fused diazocinones represent rare families of densely functionalized compounds often possessing a specific biological activity. For example, 5-hydroxymethyl-2-isopropyl-1-methyl-1,4,5,6-tetrahydro-1,4-benzodiazocin-3(2*H*)-one (BL-V8) is a selective modulator for protein kinase C.<sup>5</sup> Diazocinones fused with the pyridine ring are the HIV integrase inhibitors.<sup>6</sup> For the synthesis of fused diazocinones, a variety of methods were developed, including three-component reactions,<sup>7(a)</sup> intramolecular condensation,<sup>7(b)–(f)</sup> *N*-arylation<sup>7(g)</sup> or Friedel–Crafts,<sup>7(h)</sup> however, most of them were multi-step.

Therefore, we have revisited the reaction of substituted benzimidazoles with acylacetylenes and water. Here we report a preliminary result on the reaction between 1,5,6-trimethylbenzimidazole **1**, 1,3-diphenylprop-2-yn-1-one **2** and water.

Unlike previous publication,<sup>3</sup> the major product of this reaction proved to be the expected (see above) *N*-aryl-substituted  $\beta$ -amino enone **3** (75% yield). The corresponding benzodiazocinone **4**



Scheme 1

was isolated in 13% yield (Scheme 1).<sup>†</sup> The reaction is stereoselective with respect to product **3**: exclusively *Z*-isomer is formed. This configuration follows from the known *trans*-nucleophilic addition to acetylenes<sup>8</sup> and is additionally stabilized by the strong intramolecular H-bonding (see Scheme 1).

The reaction proceeds in boiling MeCN requiring 70 h for its completion. The reactants molar ratio **1** : **2** : water was 1 : 1 : 1. The


(*Z*)-3-[2-(*N*-Formyl-*N*-methylamino)-4,5-dimethylphenylamino]-1,3-diphenylprop-2-en-1-one **3**. 1,5,6-Trimethylbenzimidazole **1** (0.160 g, 1 mmol) in MeCN (3.5 ml) was added to a mixture of acetylene **2** (0.206 g, 1 mmol) and H<sub>2</sub>O (0.018 g, 1 mmol) in MeCN (1.5 ml). The mixture was stirred at 82 °C for 70 h. The solvent was removed, column chromatography afforded amino enone **3** (0.288 g, 75%) as a yellow powder, mp 142–143 °C (hexane–benzene, 1:1), *syn/anti* rotamers, 90:10. IR (microlayer,  $\nu/\text{cm}^{-1}$ ): 1681 (C=O), 1603 (C=C). *Syn-3*: <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>)  $\delta$ : 12.70 (s, 1H, N<sup>8</sup>H), 7.94 (m, 2H, *o*-H, COPh), 7.57 (s, 1H, N<sup>1</sup>CHO), 7.45–7.30 (m, 5H, C<sup>9</sup>Ph; 3H, *m*-H, *p*-H, COPh), 6.76 (s, 1H, H<sup>3</sup>), 6.68 (s, 1H, H<sup>6</sup>), 6.13 (s, 1H, H<sup>10</sup>), 3.05 (s, 3H, N<sup>1</sup>Me), 2.15 (s, 3H, C<sup>5</sup>Me), 2.09 (s, 3H, C<sup>4</sup>Me). <sup>13</sup>C NMR (100.62 MHz, CDCl<sub>3</sub>)  $\delta$ : 190.0 (COPh), 162.9 (N<sup>1</sup>CHO), 161.9 (C<sup>9</sup>), 139.7 (*i*-C, COPh), 137.0 (C<sup>5</sup>), 135.4 (C<sup>4</sup>), 134.9 (C<sup>7</sup>), 133.5 (*i*-C, C<sup>9</sup>Ph), 133.3 (C<sup>2</sup>), 131.5 (*p*-C, COPh), 130.0 (*p*-C, C<sup>9</sup>Ph), 128.9 (C<sup>3</sup>), 128.5 (*m*-C, C<sup>9</sup>Ph), 128.4 (*m*-C, COPh), 128.0 (*o*-C, C<sup>9</sup>Ph), 127.8 (C<sup>6</sup>), 127.4 (*o*-C, COPh), 96.8 (C<sup>10</sup>), 32.5 (N<sup>1</sup>Me), 19.4 (C<sup>5</sup>Me), 19.2 (C<sup>4</sup>Me). *Anti-3*: <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>)  $\delta$ : 12.74 (s, 1H, N<sup>8</sup>H), 8.36 (s, 1H, N<sup>1</sup>CHO), 7.92 (m, 2H, *o*-H, COPh), 7.45–7.30 (m, 5H, *o*-H, *m*-H, *p*-H, C<sup>9</sup>Ph; 3H, *m*-H, *p*-H, COPh), 6.91 (s, 1H, H<sup>6</sup>), 6.24 (s, 1H, H<sup>3</sup>), 6.13 (s, 1H, H<sup>10</sup>), 3.41 (s, 3H, N<sup>1</sup>Me), 2.15 (s, 3H, C<sup>5</sup>Me), 2.11 (s, 3H, C<sup>4</sup>Me). The carbon signals in <sup>13</sup>C NMR spectrum for *anti-3* were not collected due to low fraction of this rotamer. Found (%): C, 78.48; H, 6.35; N, 7.68. Calc. for C<sub>25</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub> (%): C, 78.10; H, 6.29; N, 7.29.

<sup>†</sup> <sup>1</sup>H and <sup>13</sup>C NMR and 2D spectra were recorded on an AV-400 Bruker BioSpin spectrometer with HMDS as an internal standard. IR spectra were recorded on a Bruker Vertex-70 instrument. 1,5,6-Trimethylbenzimidazole<sup>10</sup> **1** and benzoylphenylacetylene<sup>11</sup> **2** were prepared by published procedures. Column and thin-layer chromatography was carried out on neutral Al<sub>2</sub>O<sub>3</sub> with chloroform–benzene–ethanol (20 : 4 : 1) mixture as an eluent.

reaction was controlled by IR spectroscopy and interrupted after disappearance of the absorption band at  $2198\text{ cm}^{-1}$  belonging to the stretching vibrations of the triple bond in acylacetylene **2**.


When the reaction of benzimidazole **1** with acylacetylene **2** was conducted in toluene ( $110^\circ\text{C}$ , 96 h), the yield of amino enone **3** dropped by about 4 times, while the yield of benzodiazocinone **4** remained approximately the same as that in MeCN. Also, with 5-fold water excess or without special addition of water, the yield of benzodiazocinone **4** almost did not change.

The ring opening of benzimidazole **1** likely involves the quenching of initial zwitterion **A** by water to deliver hemiaminal-like intermediate **B** which further rearranges with the  $\text{C}^2\text{-N}^3$  bond cleavage (Scheme 2).



Scheme 2


Admittedly, the ring expansion product **4** may result from the benzoin-like condensation of amino enone **3** with further elimination of water and the corresponding prototropic rearrangement (Scheme 3).



Scheme 3

However, the experiments did not confirm this assumption. Apparently, carbanionic site of zwitterion **A** is neutralized by proton from the 2-position of the imidazole ring (Scheme 4). Bearing in mind the unfavorable orientation of the carbanionic center (*anti*- relative to  $\text{C}^2$  position), we previously assumed a similar event for the intermolecular proton transfer<sup>9(a)</sup> that was independently confirmed later by quantum-chemical calculations.<sup>9(b)-(d)</sup> Besides, the proton transfer could be mediated by the water molecule protonating the carbanion<sup>2</sup> and then hydroxide deprotonating the imidazolium ion. The carbene intermediate **C** should insert to the carbonyl group to generate intermediate **D**. The latter reacts with water to give intermediate **E** rearranging *via*  $\text{C}^2\text{-N}^3$  bond cleavage to intermediate **F**. Its final dehydration with the prototropic shift leads to benzodiazocinone **4** (see Scheme 4).

The NOESY spectrum of amino enone **3** contains cross-peaks between olefinic H-10 proton and *ortho*-protons of the



Scheme 4

phenyl groups, thus unambiguously supporting the *Z*-configuration of the olefinic fragment (Figure 1). According to NMR spectra, adduct **3** is a mixture of *syn*- and *anti*-rotamers due to the hindered rotation of the formyl moiety. In the  $^1\text{H}$  NMR spectrum of amino enone **3**, there are characteristic signals for olefinic protons H-10 (6.13 ppm), CHO (7.57 and 8.36 ppm) and NH (12.70 and 12.74 ppm) groups. In the  $^{13}\text{C}$  NMR spectrum of compound **3**, carbon atom C-10 resonates at 96.8, CHO group – at 162.9 and C=O – at 190.0 ppm. The IR spectrum of adduct **3** shows absorption bands of the C=C and C=O bonds at 1603 and  $1684\text{ cm}^{-1}$ , respectively.

The NOESY spectrum of benzodiazocinone **4** contains cross-peaks between H-4 and *ortho*-protons of phenyl rings (Figure 1). In its  $^1\text{H}$  NMR spectrum, singlet of olefinic proton H-4 resonates at 6.37 ppm. The  $^{13}\text{C}$  NMR spectrum is presented by resonance of the C=O group at 167.03 ppm. In its IR spectrum, absorption band of the C=O group appears at  $1655\text{ cm}^{-1}$ .

In conclusion, the reaction of 1,5,6-trimethylbenzimidazole with 1,3-diphenylprop-2-yn-1-one and water affords (*Z*)-3-[2-(*N*-formyl-*N*-methylamino)-4,5-dimethylphenylamino]-1,3-diphenylprop-2-en-1-one and 1,8,9-trimethyl-3,5-diphenyl-1,6-benzodiazocin-2(*1H*)-one. This result can open a straightforward




Figure 1 Cross-peaks in the NOESY spectra of amino enone **3** and benzodiazocinone **4**.

1,8,9-Trimethyl-3,5-diphenyl-1,6-benzodiazocin-2(*1H*)-one **4**. Beige powder (0.048 g, 13%), mp  $169\text{--}170^\circ\text{C}$  (ethanol). IR (microlayer,  $\nu/\text{cm}^{-1}$ ): 1655 (C=O), 1620, 1610 (C=C).  $^1\text{H}$  NMR (400.13 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.50–7.40 (m, 3H, *m*-H, *p*-H,  $\text{C}^3\text{Ph}$ ); 7.34 (m, 3H, *o*-H, *p*-H,  $\text{C}^5\text{Ph}$ ); 6.98 (m, 2H, *o*-H,  $\text{C}^3\text{Ph}$ ); 6.97 (s, 1H,  $\text{H}^7$ ); 6.83 (m, 1H,  $\text{H}^{10}$ ); 6.37 (s, 1H,  $\text{H}^4$ ); 3.24 (s, 3H,  $\text{N}^1\text{Me}$ ); 2.21 (s, 3H,  $\text{C}^9\text{Me}$ ); 2.18 (s, 3H,  $\text{C}^8\text{Me}$ ).  $^{13}\text{C}$  NMR (100.62 MHz,  $\text{CDCl}_3$ )  $\delta$ : 169.1 ( $\text{C}^5$ ), 167.0 ( $\text{C}^2$ ), 145.8 ( $\text{C}^{6a}$ ), 144.5 ( $\text{C}^3$ ), 137.3 (*i*-C,  $\text{C}^5\text{Ph}$ ), 134.9 (*i*-C,  $\text{C}^3\text{Ph}$ ), 134.2 ( $\text{C}^9$ ), 133.2 ( $\text{C}^8$ ), 131.6 (*p*-C,  $\text{C}^5\text{Ph}$ ), 130.9 ( $\text{C}^{10a}$ ), 129.2 (*p*-C,  $\text{C}^3\text{Ph}$ ), 128.8 (*m*-C,  $\text{C}^3\text{Ph}$ ), 128.7 (*m*-C,  $\text{C}^5\text{Ph}$ ), 128.4 (*o*-C,  $\text{C}^5\text{Ph}$ ), 126.9 ( $\text{C}^7$ ), 126.7 (*o*-C,  $\text{C}^3\text{Ph}$ ), 123.2 ( $\text{C}^{10}$ ), 120.1 ( $\text{C}^4$ ), 36.2 ( $\text{N}^1\text{Me}$ ), 19.6 ( $\text{C}^9\text{Me}$ ), 19.4 ( $\text{C}^8\text{Me}$ ). Found (%): C, 81.57; H, 5.96; N, 7.98. Calc. for  $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}$  (%): C, 81.94; H, 6.05; N, 7.64.

access to rare families of densely functionalized pharmaceutically promising compounds. Despite the low non-optimized yield of the benzodiazocinone, its one-step preparation from available inexpensive starting materials may acquire synthetic value since any multi-step approaches to such compounds would hardly give higher overall yields.

This work was supported by the Russian Foundation for Basic Research (grant no. 14-03-00439) and the President of the Russian Federation (programme for the support of leading scientific schools, grant no. NSh-156.2014.3).

## References

- (a) M. Adib, M. Mollahosseini, H. Yavari, M. H. Sayahi and H. R. Bijanzadeh, *Synlett*, 2004, 1086; (b) I. Yavari, M. Sabbaghan and Z. Hossaini, *Synlett*, 2006, 2501; (c) A. Shaabani, A. H. Rezayan, A. Sarvary, M. Heidary and S. W. Ng, *Tetrahedron*, 2009, **65**, 6063; (d) Kh. Pourshamsian, N. Montazeri, S. Ali-Asgari, M. M. Zeydi and E. Biazar, *Orient. J. Chem.*, 2011, **27**, 1017; (e) Y. Shen, S. Cai, C. He, X. Lin, P. Lu and Y. Wang, *Tetrahedron*, 2011, **67**, 8338; (f) K. V. Belyaeva, L. V. Andriyankova, L. P. Nikitina, A. G. Mal'kina, A. V. Afonin and B. A. Trofimov, *Tetrahedron Lett.*, 2012, **53**, 7040; (g) B. A. Trofimov, L. V. Andriyankova and K. V. Belyaeva, *Chem. Heterocycl. Compd.*, 2012, **48**, 147 (*Khim. Geterotsikl. Soedin.*, 2012, 153) and references cited therein; (h) B. A. Trofimov, L. V. Andriyankova, L. P. Nikitina, K. V. Belyaeva, A. G. Mal'kina, A. V. Afonin and I. A. Ushakov, *Synlett*, 2012, **23**, 2069; (i) K. V. Belyaeva, L. V. Andriyankova, L. P. Nikitina, A. G. Mal'kina, A. V. Afonin, I. A. Ushakov, I. Yu. Bagryanskaya and B. A. Trofimov, *Tetrahedron*, 2014, **70**, 1091.
- B. A. Trofimov, L. V. Andriyankova, L. P. Nikitina, K. V. Belyaeva, A. G. Mal'kina, L. N. Sobenina, A. V. Afonin and I. A. Ushakov, *Org. Lett.*, 2013, **15**, 2322.
- M. Acheson, J. D. Wallis and J. Woollard, *J. Chem. Soc., Perkin Trans. 1*, 1979, 584.
- J. D. Wallis, *Acta Crystallogr.*, 1992, **C48**, 897.
- I. Shcherbakova, in *Comprehensive Heterocyclic Chemistry III*, eds. A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven and R. J. K. Taylor, Elsevier, 2008, vol. 14, p. 255 and references cited therein.
- (a) J. P. Vacca, J. S. Wai, L. S. Payne, R. C. A. Isaacs, W. Han, M. Egbertson and R. Pracitto, *PCT Int. Appl., WO 2006121831 A2 20061116*, 2006 (*Chem. Abstr.*, 2006, **145**, 505478); (b) S. Lohani, Z. Peng and A. E. Mckeown, *U.S. Pat. Appl. Publ., US 20080280945 A1 20081113*, 2008 (*Chem. Abstr.*, 2008, **149**, 556676); (c) R. C. A. Isaacs, J. S. Wai and T. E. Fisher, *PCT Int. Appl., WO 2009154870 A1 20091223*, 2009 (*Chem. Abstr.*, 2009, **152**, 97513).
- (a) P. L. Reddy, D. A. Kumar, M. L. Devi, T. V. Reddy, B. V. S. Reddy and R. Narender, *Tetrahedron Lett.*, 2014, **55**, 657; (b) J. G. Topliss, *U.S. Pat. Office, US 3409608*, 1968 (*Chem. Abstr.*, 1969, **70**, 57921); (c) Yu. E. Ivanov, A. A. Yavolovsky, A. V. Mazepa and S. P. Krasnoshchekaya, *Chem. Heterocycl. Compd.*, 2003, **39**, 250 (*Khim. Geterotsikl. Soedin.*, 2003, 281); (d) O. Migliara, S. Plescia, P. Diana, V. D. Stefano, L. Camarda and R. Dall'Olio, *Arkivoc*, 2004, v. 44; (e) V. V. Potapov, N. A. Fetisova, A. V. Nikitin and A. V. Ivachtchenko, *Tetrahedron Lett.*, 2009, **50**, 2790; (f) A. Mishra and S. Batra, *Eur. J. Org. Chem.*, 2010, 4832; (g) T. Yang, C. Lin, H. Fu, Y. Jiang and Y. Zhao, *Org. Lett.*, 2005, **7**, 4781; (h) S. BouzBouz and M. Sanselme, *Tetrahedron Lett.*, 2009, **50**, 5884.
- (a) S. I. Miller and R. Tanaka, in *Selective Organic Transformations*, ed. B. S. Thyagarajan, Wiley-Interscience, New York, 1970, vol. 1, p. 143; (b) J. I. Dickstein and S. I. Miller, in *The Chemistry of the Carbon–Carbon Triple Bond*, ed. S. Patai, Wiley, New York, 1978, vol. 2, p. 814.
- (a) B. A. Trofimov, L. V. Andriyankova, K. V. Belyaeva, A. G. Mal'kina, L. P. Nikitina, A. V. Afonin and I. A. Ushakov, *J. Org. Chem.*, 2008, **73**, 9155; (b) D. Wei and M. Tang, *J. Phys. Chem. A*, 2009, **113**, 11035; (c) S. Li, D. Wei, Y. Zhu and M. Tang, *Comp. Theor. Chem.*, 2013, **1017**, 168; (d) Y. Wang, J. Y. Ren, S. J. Qi, D. H. Wei and M. S. Tang, *Comp. Theor. Chem.*, 2014, **1049**, 35.
- O. V. Starikova, G. V. Dolgushin, L. I. Larina, T. N. Komarova and V. A. Lopyrev, *Arkivoc*, 2003, **xiii**, 119.
- A. S. Zanina, S. I. Shergina, I. E. Sokolov and R. N. Myasnikova, *Russ. Chem. Bull.*, 1995, **44**, 689 (*Izv. Akad. Nauk., Ser. Khim.*, 1995, 710).

Received: 9th December 2014; Com. 14/4523